Price
No data yet.
Social Signal Score
Analyst Ratings
8 analystsRevenue
$174.0KAnalyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- Bruce Culleton
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 231
- Beta
- 1.90
- Country
- US
- Piotroski score
- 1 / 9 (Weak)
- Altman Z-score
- -4.90
Financials
Revenue
$174.0K+128.9%Net Income
$-35.59MEBITDA
$-50.55MFree Cash Flow
$-39.88MEPS (diluted)
$-0.17Shares Outstanding (diluted)
207.76M+80.5%Operating Expenses
$53.93MCash & Debt
$141.86MQuote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $893.0K | $-68.99M | $-0.52 |
| 2024 | $76.0K | $-61.19M | $-0.62 |
| 2023 | $0.00 | $-35.47M | $-0.57 |
| 2022 | $0.00 | $-108.03M | $-1.76 |
| 2021 | $0.00 | $-55.15M | $-1.73 |
| 2020 | $0.00 | $-26.75M | $-0.14 |
| 2019 | $0.00 | $-79.61M | $-1.01 |
Valuation
PROKhas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·4d ago·Neutral
ProKidney Names Farah Ali, M.D., M.S., Chief Medical Officer Dr. Ali expands her role at ProKidney, bringing experience as a board-certified pediatric nephrologist and clinical development leader as the Company prepares for anticipated clinical milestones and regulatory filings Dr. Ali expands her role at ProKidney, bringing experience as a board-certified pediatric nephrologist and clinical development leader as the Company prepares for anticipated clinical milestones and regulatory filings
View source ↗ - Newsmarketbeat.com·25d ago·Positive
ProKidney Targets Q2 2027 Phase III Readout as Rilparencel Enrollment Surpasses 500 ProKidney NASDAQ: PROK said it remains on track to report top-line results from the interim analysis of its Phase III PROACT 1 study in the second quarter of 2027, following stronger-than-expected patient recruitment for its investigational autologous cell therapy, rilparencel.
View source ↗ - Newsseekingalpha.com·26d ago·Positive
ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript ProKidney Corp. (PROK) Discusses Rilparencel Mechanism and Role in Advanced Chronic Kidney Disease Transcript
View source ↗ - Newsglobenewswire.com·31d ago·Neutral
ProKidney to Host Virtual KOL Event to Recap Mechanism of Action Data Presented at ASN Kidney Week and Provide a Corporate Update WINSTON-SALEM, N.C., Oct. 22, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that it will host a virtual key opinion leader (KOL) event on Tuesday, October 27, 2026, at 10:30 AM ET. To register, click here.
View source ↗ - Newsglobenewswire.com·51d ago·Neutral
…ts Selected for Presentation at the American Society of Nephrology's Kidney Week 2026 WINSTON-SALEM, N.C., Oct. 02, 2026 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the “Company”), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today announced that the Company will present eight abstracts, including one oral presentation, at the upcoming American Society of Nephrology's (ASN) Kidney Week being held from October 21-25, 2026, in D…
View source ↗ - Newsseekingalpha.com·100d ago·Negative
ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade) ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase 3 PROACT data in 2027 is pivotal. PROK's cash runway extends only into mid-2027, with just $181.6M remaining and ongoing high cash burn, raising 'going concern' doubts.
View source ↗
Earnings
Wed, Mar 17(in 4 months)
Consensus estimate $-0.14 per share
Typical surprise +0.0% (median, so one quarter with a near-zero estimate can't distort it)
- Thu, Nov 12$-0.17 vs $-0.16miss
- Mon, Aug 10$-0.15 vs $-0.14miss
- Fri, May 15$-0.14 vs $-0.13miss
- Wed, Mar 18$-0.14 vs $-0.16beat
- Mon, Nov 10$-0.12 vs $-0.12beat
- Tue, Aug 12$-0.13 vs $-0.14beat
Estimates and results for PROK via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by PROK officers and directors.
- Bought
- $76.5m
- Sold
- $2.1m
14 trades
17 trades
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
- Pereira Brian Jgsold
69 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in PROK.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.
